Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 14/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15993345 | 0.87 | DHODH (0.58) | DHODHLMNAKMT2AMAPTNPC1 | |
| SCHEMBL15993418 | 0.82 | DHODH (0.53) | DHODHLMNAKMT2AMAPTNPC1 | |
| SCHEMBL27039800 | 0.82 | DHODH (0.53) | DHODHLMNAKMT2AMAPTNPC1 | |
| SCHEMBL19782726 | 0.81 | LMNA (0.56) | DHODHLMNAKMT2AMAPTNPC1 | |
| SCHEMBL17485927 | 0.79 | NPC1 (0.57) | LMNAKMT2AMAPTNPC1NPSR1 | |
| SCHEMBL19782992 | 0.78 | DHODH (0.56) | DHODHKMT2AMAPTNPC1NPSR1 | |
| SCHEMBL29078713 | 0.78 | DHODH (0.56) | DHODHLMNAKMT2AMAPTNPC1 | |
| SCHEMBL3403482 | 0.78 | LMNA (0.62) | DHODHLMNAKMT2ANPC1KDM4E | |
| SCHEMBL18236334 | 0.78 | ALDH1A1 (0.69) | DHODHLMNAKMT2ANPC1KDM4E | |
| SCHEMBL15993447 | 0.77 | DHODH (0.54) | DHODHLMNAKMT2AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| WO-2014159938-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159938-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | AADAT, ABAT, AASDHPPT | DHODH 80/4885LMNA 4407/4885KMT2A 1460/4885 |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | ABAT, AADAT, AASDHPPT | DHODH 128/4885LMNA 3254/4885KMT2A 2026/4885 |
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | AADAT, ABAT, AASDHPPT | DHODH 80/4885LMNA 4407/4885KMT2A 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.